. 2022 Jul 28;27(30):2100809. doi: 10.2807/1560-7917.ES.2022.27.30.2100809

Table 1. Characteristics of migrants living with HIV, diagnosed before or after immigration, stratified by regions of origin, Denmark, 1995–2020 (n = 2,166).

Characteristics		Region of origin
		All n = 2,166		Sub-Saharan Africa n = 891		Western countries n = 446		East and South Asia n = 403		Eastern Europe n = 171		Other n = 255
		n	%	n	%	n	%	n	%	n	%	n	%
Diagnosed after immigration		1,514	70	655	74	250	56	293	73	128	75	188	74
Age in years, median (IQR)		33 (28–40)		32 (28–38)		37 (31–43)		34 (28–40)		31 (27–37)		34 (28–41)
Sex^a	Males	830	55	214	33	219	88	152	52	89	70	156	83
Sex^a	Females	682	45	440	67	31	12	141	48	39	30	31	16
Reported HIV transmission modes	Sex between men	388	26	16	2	151	60	85	29	54	42	82	44
	Sex between men and women	873	58	551	84	62	25	156	53	41	32	63	34
	Injecting drug use	50	3	5	1	16	6	8	3	9	7	12	6
	Other/unknown	203	13	83	13	21	8	44	15	24	19	31	16
HIV-RNA values^b	Measurement at LTC	1,335	88	562	86	215	86	277	95	115	90	166	88
	HIV-RNA (log₁₀ copies/ml), median (IQR)	4.7 (3.9–5.2)		4.5 (3.7–5.2)		4.8 (4.0–5.4)		4.8 (4.0–5.3)		4.6 (4.0–5.3)		4.7 (4.1–5.2)
	HIV-RNA < 200 copies/ml	78	6	42	7	15	7	13	5	≤ 4	≤ 3	≤ 4	≤ 2
CD4⁺ T-cell counts^b	Measurement at LTC	1,421	94	615	94	229	92	283	97	120	94	174	93
CD4⁺ T-cell counts^b	CD4⁺ T-cell count (cells/µL), median (IQR)^c	290 (130–460)		250 (120–410)		362 (170–557)		276 (75–439)		341 (189–524)		341 (177–510)
Late-stage HIV	Late presenters^d	856	60	416	68	107	47	181	64	63	53	89	51
	Advanced HIV disease^e	530	37	259	42	66	29	123	43	33	28	49	28
	AIDS	175	12	74	11	21	8	55	19	8	6	17	9
Diagnosed before immigration		652	30	236	26	196	44	110	27	43	25	67	26
Age in years, median (IQR)		33 (28–40)		33 (28–38)		36 (31–46)		31 (27–37)		30 (26–38)		32 (26–41)
Sex	Males	361	55	70	30	165	84	47	43	25	NA	54	81
Sex	Females	291	45	166	70	31	16	63	57	18	NA	13	19
Reported HIV transmission modes	Sex between men	202	31	10	4	114	58	26	24	16	NA	36	54
	Sex between men and women	279	43	172	73	29	15	55	50	12	NA	11	16
	Injecting drug use	20	3	≤ 4	≤ 2	9	5	≤ 4	≤ 4	5	NA	≤ 4	≤ 6
	Other/unknown	151	23	52	22	44	22	26	24	10	NA	19	28
HIV-RNA values^f	Measurement at LTC	567	87	199	84	174	89	98	89	39	NA	57	85
	HIV-RNA (log₁₀ copies/ml), median (IQR)	2.1 (1.3–4.4)		3.6 (1.3–4.7)		1.3 (1.3–3.5)		2.7 (1.3–4.7)		1.4 (1.3–4.0)		1.6 (1.3–3.5)
	HIV-RNA < 200 copies/ml	296	52	68	34	119	68	45	46	25	NA	39	68
CD4⁺ T-cell counts^f	Measurement at LTC	553	85	200	85	164	84	99	90	34	NA	56	84
CD4⁺ T-cell counts^f	CD4⁺ T-cell count (cells/µL), median (IQR)^c	430 (250–630)		311 (160–462)		525 (350–770)		440 (260–610)		550 (373–757)		521 (361–670)
Late-stage HIV	CD4⁺ T-cell < 350 cells/µL/AIDS^f	218	39	118	59	44	27	35	35	8	NA	13	23
	CD4⁺ T-cell < 200 cells/µL/AIDS^f	122	22	70	35	22	13	21	21	≤ 4	NA	5	9
	AIDS	48	7	24	10	11	6	9	8	≤ 4	NA	≤ 4	≤ 6

AIDS: acquired immunodeficiency syndrome; IQR: interquartile range; LTC: linkage to care; NA: not applicable.

All characteristics were collected at date of LTC.

^a Missing information on sex was ≤ 4 (≤ 0.2%) in SSA and in Other.

^b Data were missing for some MLWH for the following variables: HIV-RNA (n = 179) and CD4⁺ T-cell count (n = 93) and were excluded from analyses of HIV-RNA, CD4⁺ T-cell count and late presentation/advanced HIV disease.

^c CD4⁺ T-cell normal range: 500–1,500 cells/µl.

^d Presenting with CD4⁺ T-cell count < 350 cells/µl or with an AIDS-defining event regardless of CD4⁺ T-cell count.

^e Presenting with CD4⁺ T-cell count < 200 cells/µl or with an AIDS-defining event regardless of CD4⁺ T-cell count.

^f Data were missing for some MLWH for the following variables: HIV-RNA (n = 85) and CD4⁺ T-cell count (n = 99) and were excluded from analyses of HIV-RNA and CD4⁺ T-cell count.